Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
| ▸ | CDC25A | P30304 | 4/20 | 0.77 |
| ▸ | POLA1 | P09884 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.65 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19232373 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL4739364 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL15372968 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL11371121 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL4739362 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL24403430 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL10052613 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL13214256 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL12205280 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL15289783 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10824006-B2 | Liquid crystal display device | SHARP KABUSHIKI KAISHA (JP) | 2020-11-03 | — | — | US | disclosed |
| US-20190324320-A1 | LIQUID CRYSTAL DISPLAY DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2019-10-24 | — | — | US | disclosed |
| EP-2520972-B1 | Liquid crystal display device alignment film, and method for manufacturing the same | SAMSUNG DISPLAY CO LTD (KR) | 2019-09-04 | — | — | EP | disclosed |
| US-20190219856-A1 | LIQUID CRYSTAL PANEL, SWITCHABLE MIRROR PANEL AND SWITCHABLE MIRROR DISPLAY | SHARP KABUSHIKI KAISHA (JP) | 2019-07-18 | — | — | US | disclosed |
| US-20180164616-A1 | LIQUID CRYSTAL DISPLAY DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180164616-A1 | LIQUID CRYSTAL DISPLAY DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20170218272-A1 | ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9723769-B2 | Liquid crystal display device, alignment film, and methods for manufacturing the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-08-01 | — | — | US | disclosed |
| US-9684207-B2 | Polymer for alignment films, and liquid crystal display device | SHARP KABUSHIKI KAISHA (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20160122652-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2016-05-05 | — | — | US | disclosed |
| US-20130271712-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND METHOD FOR MANUFACTURING LIQUID CRYSTAL DISPLAY DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2013-10-17 | — | — | US | disclosed |
| US-8345201-B2 | Alignment film material comprising polyimide and a vinyl-type monomer, alignment film comprising polyimide and polyvinyl compound, method of forming the alignment film, and liquid crystal display having the same | SHARP KABUSHIKI KAISHA (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20120194771-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND METHOD FOR MANUFACTURING SAME | SHARP KABUSHIKI KAISHA (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120094015-A1 | Liquid crystal alignment agent and liquid crystal alignment film formed therefore and manufacturing method thereof | CHI-MEI CORPORATION | 2012-04-19 | — | — | US | disclosed |
| US-20120094015-A1 | Liquid crystal alignment agent and liquid crystal alignment film formed therefore and manufacturing method thereof | CHI-MEI CORPORATION | 2012-04-19 | — | — | US | disclosed |
| US-20120058262-A1 | Liquid crystal alignment agent and liquid crystal alignment film formed therefore and manufacturing method thereof | CHI-MEI CORPORATION | 2012-03-08 | — | — | US | disclosed |
| US-20120058262-A1 | Liquid crystal alignment agent and liquid crystal alignment film formed therefore and manufacturing method thereof | CHI-MEI CORPORATION | 2012-03-08 | — | — | US | disclosed |
| US-20090280236-A1 | Liquid crystal alignment agent and liquid crystal alignment film formed therefore and manufacturing method thereof | CHI-MEI CORPORATION | 2009-11-12 | — | — | US | disclosed |
| US-20090280236-A1 | Liquid crystal alignment agent and liquid crystal alignment film formed therefore and manufacturing method thereof | CHI-MEI CORPORATION | 2009-11-12 | — | — | US | disclosed |
| US-20080138285-A1 | Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound | FUJIFILM CORPORATION (JP) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138285-A1 | Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound | PHOSPHO1, SGMS1, SGMS2 | VDR 1016/4885USP2 3998/4885CDC25A 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.